Analysis of Biomarkers and Marginal Bone Loss in Platform‐Switched and Nonplatform‐Switched Implants: A Randomized Clinical Trial
Necla Asli Kocak-Oztug, Gamze Zeynep Adem-Siyli, Orkhan Abishev, Şule Batu, Yegane Güven, Ali Çekici, Aslan Gökbuget, Erhan Fıratlı, Serdar Cintan
Abstract
Objectives . To compare the peri‐implant crevicular fluid (PICF) biomarker levels, peri‐implant status, and marginal bone level (MBL) differences of implants restored with randomly assigned nonplatform‐switched (NPS) or platform‐switched (PS) abutments. Methods . Ninety‐four implants in 27 subjects were included in this study. Receptor activator of nuclear factor kappa‐B ligand (RANKL), osteoprotegerin (OPG), interleukin‐1 β (IL‐1 β ), monocyte chemotactic protein‐1 (MCP‐1) levels in PICF, peri‐implant health, and the change in the MBL were evaluated at the time of restoration ( T 1 ) and after 12 months ( T 2 ). Results . The IL‐1 β levels decreased and the RANKL, OPG, and MCP‐1 levels increased from T 1 to T 2 ( P < 0.05) in both groups. RANKL/OPG ratio at T 1 , MCP‐1 levels at T 2 , and the MCP‐1 change from T 1 to T 2 were lower in the PS group than in the NPS group ( P < 0.05). MBL change was lower (0.51 ± 0.31 mm) in the PS group than that (0.75 ± 0.29 mm) in the NPS group at T 2 ( P < 0.001). Peri‐implant health status between the study groups was negligible. Conclusion . PS was superior to NPS regarding the preservation of MBL. Higher MCP‐1 levels, altered RANKL/OPG ratio, and lower OPG levels in the NPS group could be associated with subclinical peri‐implant bone remodeling.